A detailed history of Nuveen Asset Management, LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 156,787 shares of TARS stock, worth $4.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156,787
Previous 236,442 33.69%
Holding current value
$4.32 Million
Previous $4.79 Million 19.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$19.61 - $39.22 $1.56 Million - $3.12 Million
-79,655 Reduced 33.69%
156,787 $5.7 Million
Q4 2023

Feb 14, 2024

BUY
$12.98 - $20.73 $1.7 Million - $2.71 Million
130,841 Added 123.9%
236,442 $4.79 Million
Q3 2023

Nov 14, 2023

BUY
$14.75 - $24.62 $533,050 - $889,742
36,139 Added 52.03%
105,601 $1.88 Million
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $295,983 - $502,174
25,582 Added 58.3%
69,462 $1.26 Million
Q1 2023

May 15, 2023

SELL
$11.92 - $16.27 $61,805 - $84,359
-5,185 Reduced 10.57%
43,880 $551,000
Q4 2022

Feb 14, 2023

SELL
$14.12 - $18.72 $112,296 - $148,880
-7,953 Reduced 13.95%
49,065 $719,000
Q3 2022

Nov 14, 2022

SELL
$14.08 - $18.5 $28,892 - $37,962
-2,052 Reduced 3.47%
57,018 $976,000
Q2 2022

Aug 15, 2022

BUY
$11.08 - $19.08 $413,361 - $711,817
37,307 Added 171.42%
59,070 $862,000
Q3 2021

Nov 12, 2021

SELL
$21.45 - $29.22 $84,942 - $115,711
-3,960 Reduced 15.39%
21,763 $496,000
Q2 2021

Aug 16, 2021

BUY
$27.16 - $38.59 $295,799 - $420,283
10,891 Added 73.43%
25,723 $745,000
Q1 2021

May 17, 2021

BUY
$27.37 - $47.25 $129,843 - $224,154
4,744 Added 47.03%
14,832 $478,000
Q4 2020

Feb 16, 2021

BUY
$19.17 - $49.62 $193,386 - $500,566
10,088 New
10,088 $417,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $734M
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.